PacBio Announces New Nanobind PanDNA Kit Enabling HiFi Optimized DNA Extraction Solutions

Rhea-AI Summary

PacBio (PACB) announces the launch of PanDNA, a Nanobind DNA extraction kit designed to enable high-throughput extraction of high molecular weight DNA for HiFi sequencing. The PanDNA kit expands the range of sample types suitable for long-read sequencing, including cells, bacteria, blood, tissue, plant nuclei, and insects. The existing Nanobind HT CBB kit has been updated to support two new sample types – animal blood and bacteria – and can accommodate 96 samples per run. The new PanDNA kit is expected to be available in February 2024, while the Nanobind HT CBB kit is available now.

Positive

• PacBio introduces the PanDNA Nanobind DNA extraction kit to support high-quality, high molecular weight DNA extraction for HiFi sequencing.
• The PanDNA kit expands the range of sample types suitable for long-read sequencing, including cells, bacteria, blood, tissue, plant nuclei, and insects.
• The existing Nanobind HT CBB kit has been updated to support two new sample types – animal blood and bacteria – and can accommodate 96 samples per run.
• The new PanDNA kit is expected to be available for purchase and shipment in February 2024.

Negative

• None.

Genomics Research Analyst

The introduction of PacBio's PanDNA kit represents a significant advancement in the field of genomics, particularly in the area of long-read sequencing. The ability to extract high molecular weight (HMW) DNA from a broader range of sample types, including animal blood and bacteria, is pivotal for complex genomic studies. High molecular weight DNA is essential for applications such as de novo genome assembly, where longer DNA fragments can lead to more contiguous and accurate assemblies.

For genomics research, the compatibility with high-throughput settings is critical. The capacity to accommodate 96 samples per run is a substantial increase in efficiency, which can accelerate the pace of research and reduce costs. The impact on large-scale projects, like the Darwin Tree of Life project mentioned, could be profound, as the ability to process large numbers of samples quickly is a key requirement for such ambitious endeavors.

Biotechnology Market Analyst

From a market perspective, the launch of the PanDNA kit by PacBio could potentially open up new revenue streams and strengthen its position in the competitive landscape of sequencing technology providers. By offering a product that simplifies and expedites the DNA extraction process, PacBio may see an increase in demand for its sequencing solutions, particularly the Revio system which is designed to work in tandem with these kits.

Investors should monitor the adoption rate of the PanDNA kit closely, as it could serve as an indicator of PacBio's future financial performance. Increased sales and positive customer feedback can affirm the company's strategic direction and could influence stock market performance. It's also worth noting that the ability to cater to a niche yet growing demand for high-throughput, high-fidelity sequencing solutions could position PacBio favorably against competitors.

Laboratory Automation Specialist

The emphasis on compatibility with automated platforms is a reflection of the ongoing trend towards laboratory automation in genomics research. Automation not only improves reproducibility and precision but also enables researchers to handle larger datasets with reduced manual intervention. PacBio's alignment with this trend, by ensuring their new kits work with existing automation systems, is a strategic move to cater to the needs of modern genomic laboratories.

Furthermore, the ease of integration with automation platforms could encourage laboratories to upgrade their systems to include PacBio's solutions, potentially leading to an increase in market share for automated sequencing technologies. The simplification of the workflow for DNA extraction, as well as the support for a variety of sample types, could significantly reduce the barrier to entry for labs looking to adopt long-read sequencing technologies.

Existing HT CBB Kit Enables High-Throughput Extraction of HMW DNA Tailored for HiFi With an Updated Workflow for Animal Blood and Bacteria

MENLO PARK, Calif., Jan. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PanDNA, a versatile Nanobind DNA extraction kit. This new offering expands the array of sample types suitable for long-read sequencing, including cells, bacteria, blood, tissue, plant nuclei, and insects.

Nanobind kits are designed for researchers to efficiently extract high-quality, high molecular weight DNA across a wide range of sample types. These kits are versatile, accommodating both manual (Nanobind PanDNA kit) and high-throughput (Nanobind CBB HT kit) settings. Their simple, rapid protocol is compatible with platforms from PacBio's Compatible automation providers.

In addition, based on customer feedback, the existing high-throughput extraction Nanobind HT CBB kit will now support two new sample types – animal blood and bacteria – and can accommodate 96 samples per run.

"The new PanDNA kit will be the go-to kit for extracting DNA optimized for HiFi sequencing," said Jeff Eidel, Chief Commercial Officer at PacBio. "We continue to enable our customers with products such as the PanDNA kit that support researchers to complete accurate genome assemblies, identify structural variants, and explore complex biological systems in extraordinary detail using our Revio sequencing system."

"Nanobind high molecular weight DNA extraction is a game-changer for us and having one universal kit for all supported samples is very convenient," said Igor Stevanovski, Research Assistant at the Genomic Technologies Lab, Garvan Institute of Medical Research – one of Australia's premier medical research institutes. "The flexibility offered by the PanDNA kit will support our broad research community to answer those key questions and make important biological discoveries."

"The Darwin Tree of Life project aims to generate high quality genomes for 70,000 species of plants, fungi, animals and protists across Britain and Ireland. High-throughput solutions such as the Nanobind CBB HT kit are critical for efforts like these," said Caroline Howard, Senior Scientific Manager, Tree of Life Programme at the Wellcome Sanger Institute. "The Nanobind kits combined with the Revio system address these needs by significantly increasing throughput. Using the kits, we were able to generate 30x coverage of HiFi data sufficient for de novo assembly."

The new PanDNA kit is expected to be available for purchase and shipment in February 2024. The Nanobind HT CBB kit is available now. For more information, visit the Nanobind extraction kit page here.

About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to future availability, uses, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, including Nanobind PanDNA kits; statements regarding DNA extraction across a wide range of sample types; PanDNA kits as a go-to kit for HiFi sequencing and its ability to support a broad research community; among other future events. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this press release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. These risks include, but are not limited to, challenges inherent in developing, manufacturing, launching, marketing and selling new products; potential product performance and quality issues and potential delays in development and commercialization timelines; rapidly changing technologies and extensive competition in genomic sequencing that could make the products PacBio is developing obsolete or non-competitive; and third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights. Readers are strongly encouraged to read the full cautionary statements contained in PacBio's filings with the Securities and Exchange Commission, including the risks set forth in PacBio's Forms 8-K, 10-K, and 10-Q. PacBio disclaims any obligation to update or revise any forward-looking statements.

Contacts

Investors:
Todd Friedman
ir@pacificbiosciences.com                                   

Media:
Lizelda Lopez
pr@pacificbiosciences.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/pacbio-announces-new-nanobind-pandna-kit-enabling-hifi-optimized-dna-extraction-solutions-302034274.html

SOURCE Pacific Biosciences of California, Inc.

What is the new offering announced by PacBio?

PacBio has announced the launch of PanDNA, a Nanobind DNA extraction kit designed to enable high-throughput extraction of high molecular weight DNA for HiFi sequencing.

What sample types are suitable for long-read sequencing with the PanDNA kit?

The PanDNA kit expands the range of sample types suitable for long-read sequencing, including cells, bacteria, blood, tissue, plant nuclei, and insects.

What updates have been made to the existing Nanobind HT CBB kit?

The existing Nanobind HT CBB kit has been updated to support two new sample types – animal blood and bacteria – and can accommodate 96 samples per run.

When is the new PanDNA kit expected to be available for purchase and shipment?

The new PanDNA kit is expected to be available for purchase and shipment in February 2024.

Where can more information about the Nanobind extraction kit be found?

For more information, visit the Nanobind extraction kit page here.